TMCnet News
MASS Opportunities 2006 Presenter and Sponsor ProfilesBOSTON --(Business Wire)-- MASS Opportunities 2006 takes place November 2, 2006 at the Logan Airport Hilton. For in-depth information about the event, visit http://massbio.org/events/mass_opps/. Below are profiles from MASS Opportunities 2006 presenters and sponsors. Breaking news releases are available at http://www.tradeshownews.com and the virtual newsroom link on http://massbio.org/events/mass_opps/presenting_companies.php. Business Wire is the official news wire service for MASS Opportunities 2006. Company: Acambis Ticker Symbol & Exchange: LSE:ACM & NASDAQ:ACAM Media Contact: Tracy Paczkowski Investor Relations Contact: Lyndsay Wright Phone: 617-761-4200 E-mail: [email protected] Web: http://www.acambis.com Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. It is headquartered in Cambridge, UK, and has operations in Cambridge and Canton, Mass., and in Rockville, Md. Acambis' development-stage pipeline includes an investigational vaccine against Japanese encephalitis, which is undergoing Phase 3 clinical testing; ChimeriVax(TM)-West Nile, which is the most advanced investigational vaccine against the West Nile virus; and the only vaccine in development against Clostridium difficile, a leading cause of hospital-acquired infections. Acambis is recognized internationally as the leading producer of smallpox vaccines, which it manufactures for emergency-use stockpiles for the US Government and governments worldwide. Company: ArQule, Inc. Ticker Symbol & Exchange: NASDAQ: ARQL Investor Relations Contact: William Boni Phone: 781-994-0614 E-mail: [email protected] Web: http://www.arqule.com ArQule is an oncology-focused biotechnology company with complementary expertise in molecular biology and chemistry technology. The Company's strengths in molecular biology enable it to affect certain key mechanisms that are common across multiple cancers and thus to halt tumor formation and progression. Its chemistry capabilities have made it possible to imbue its product candidates with pre-selected drug-like characteristics and a high degree of specificity for cancer cells. ArQule is currently conducting clinical trials with products generated from these two scientific platforms. Company: Arteriocyte, Inc. Media Contact: Don Brown Investor Relations Contact: Don Brown Phone: 617-794-2711 E-mail: [email protected] Web: http://www.arteriocyte.com Arteriocyte is a clinical stage research and development biotechnology company developing proprietary, adult derived stem cell therapies for the treatment of ischemia in patients suffering from coronary artery disease, peripheral vascular disease, stroke, and neurodegenerative diseases. The company's research focuses on utilizing stem cells to stimulate angiogenesis (new vessel growth). The company recently completed enrollment of a Phase I safety trial in the US (under an FDA IND) for its lead product (ACY001) in patients suffering Chronic Ischemia. The clinical study completed enrollment in June 2006, and the company presented its first clinical update at TCT2006. The company plans to initiate its Phase II clinical trial in the near future. The company is privately funded, has raised $2.4 Million to date, and is currently raising a Series A investment. Company: AVANT Immunotherapeutics, Inc. Ticker Symbol & Exchange: NASDAQ:AVAN Media Contact: Joan Kureczka Investor Relations Contact: Paula Freeman Phone: 781-433-3108 E-mail: [email protected] Web: http://www.avantimmune.com AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and immunotherapeutics that harness the human immune system to prevent and treat disease. They address a wide range of applications including bacterial and viral diseases, cardiovascular diseases, biodefense and human food safety. AVANT has a pipeline of bacteria-fighting products for biodefense, travelers' vaccines, and global health needs based on AVANT'S rapid-protecting, single-dose, oral and temperature stable vaccine technologies. Five products are in clinical development, including single-dose, oral vaccines that protect against important disease causing agents, a novel vaccine for cholesterol management, and a treatment to reduce complement-mediated tissue damage associated with cardiac bypass surgery. Company: CombinatoRx, Incorporated Ticker Symbol & Exchange: CRXX Media Contact: Gina Nugent Investor Relations Contact: Gina Nugent Phone: 617-301-7099 E-mail: [email protected] Web: http://www.combinatorx.com CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit http://www.combinatorx.com. Company: Dynogen Pharmaceuticals, Inc. Media Contact: Heather Savelle Investor Relations Contact: Heather Savelle Phone: 781-839-5149 E-mail: [email protected] Web: http://www.dynogen.com Dynogen is a clinical-stage company developing a portfolio of more effective treatments for gastrointestinal and genitourinary disorders. The Company is focused on capturing value in attractive and untapped markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The Company leverages its development expertise to identify promising clinical compounds and rapidly advance them towards registration. Dynogen currently has multiple double-blind, placebo-controlled Phase 2 studies underway. http://www.dynogen.com. Company: Elusys Therapeutics, Inc. Media Contact: LaVoie Strategic Communications Investor Relations Contact: LaVoie Strategic Communications Phone: 978-745-4200 E-mail: [email protected] Web: http://www.elusys.com Elusys Therapeutics, Inc. (Elusys) is a privately-held biopharmaceutical company focused on the development of targeted anti-infective drugs using proprietary Heteropolymer (HP) Antibodies. Elusys' HP Antibody technology has demonstrated a unique ability to clear and destroy pathogens and is a platform for the development of a deep pipeline of novel drug candidates targeted against bacterial, viral and fungal infections. Company: EyeGate Pharmaceuticals, Inc. Media Contact: Bryan P. Murphy Investor Relations Contact: Dory Valiquette Phone: 978-745-4200 ext. 105/106 E-mail: [email protected] Web: http://www.eyegatepharma.com EyeGate Pharmaceuticals, Inc. is a privately-held, specialty pharmaceutical company using its proprietary current regulated iontophoresis technology to safely and non-invasively deliver therapeutics to the anterior and posterior chambers of the eye. EyeGate is addressing the need for an alternative mode of delivery since there are safety and efficacy drawbacks posed by current ocular delivery applications, such as injections or implants. EyeGate is the first company to demonstrate clinical significance utilizing iontophoresis for the local treatment of ocular conditions. EyeGate is developing its internal pipeline of products for severe uveitis and glaucoma and will pursue partnerships for larger market indications such as AMD. Company: Genstruct Media Contact: Karen Higgins, A & E Communications, Inc Phone: 610-831-5723 E-mail: [email protected] Web: http://www.genstruct.com Founded in 2002, Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders and inflammation. Genstruct has developed proprietary technologies for the discovery of biomarkers, disease pathways and compound mechanisms of action (MOA). Genstruct engages in internal discovery and external development partnerships which apply systems biology to accelerate and increase the output of drug discovery and development programs. The privately held company is based in Cambridge, Mass., and its investors include Flagship Ventures and A. M. Pappas & Associates. Company: NUCRYST Pharmaceuticals Corp. Ticker Symbol & Exchange: NASDAQ:NCST & TSX: NCS Media Contact: Carrie Gonzalez Investor Relations Contact: David Wills Phone: 416-504-8464 E-mail: [email protected] Web: http://www.nucryst.com NUCRYST Pharmaceuticals (NASDAQ:NCST & TSX:NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products under their Acticoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST's SILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The company has developed its proprietary nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, referred to as NPI 32101. Company: Pericor Science Inc Ticker Symbol & Exchange: privately held Media Contact: Slowey/McManus Communications Phone: 781-419-4015 E-mail: [email protected] Web: http://www.pericor.com Pericor Science is a privately held biopharmaceutical company engaged in commercialization of its TransLink(TM) system for drug delivery. The TransLink(TM) platform enables the redesign of existing drugs or active agents to create a new therapeutic resulting in improved efficacy, durability, safety and/or sustained release. In 2005, Pericor licensed its first product, PCS 101, to a major global pharmaceutical company for development of a new treatment for Dry Eye Syndrome. Its second product, PTI 101, is a direct thrombin inhibitor that targets restenosis and thrombosis in interventional cardiology. It is currently slated for preclinical testing. Company: Pressure BioSciences, Inc. Ticker Symbol & Exchange: PBIO Media Contact: Richard T. Schumacher Investor Relations Contact: Richard T. Schumacher Phone: 508-580-1818 ext. 131 E-mail: [email protected] Web: http://www.pressurebiosciences.com Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to rapidly, repeatedly, and safely control bio-molecular interactions. We currently hold 13 US/5 foreign patents covering multiple applications of PCT, including genomic and proteomic sample preparation, pathogen inactivation, enzyme control, immunodiagnostics, and protein purification. We market the PCT Sample Preparation System, an excellent tool for the extraction of DNA/RNA/proteins/small molecules from a variety of animal/plant/microbe/human cells and tissues. Company: ProNAi Therapeutics Media Contact: Mario Fante, Aviator PR, 617-763-9887 Investor Relations Contact: Dr. Richard D. Gill, President and CEO Phone: 269-372-3289 E-mail: [email protected] Web: http://www.pronai.com ProNAi Therapeutics is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is developing multiple DNAi-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin's lymphoma, prostate, breast, and colon cancers. ProNAi's lead drug candidate, PNT-100, currently in preclinical development, has demonstrated in vivo efficacy in a variety of human tumor xenograft models. ProNAi is exploring the potential of DNAi-based therapies for indications such as diabetes, Alzheimer's and inflammatory disease. Company: Pro-Pharmaceuticals, Inc. Ticker Symbol & Exchange: PRW:AMEX Media Contact: Tony Squeglia Investor Relations Contact: Tony Squeglia Phone: 617-559-0033 E-mail: [email protected] Web: http://www.pro-pharmaceuticals.com Pro-Pharmaceuticals is an early stage company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections. Initially, the product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs. DAVANAT(R), the Company's lead product candidate, is a complex carbohydrate drug that when given in combination with chemotherapeutic agents demonstrates reduced toxicity and increased efficacy by targeting the delivery of the chemotherapy to the tumor. The Company has completed a Phase l trial for all solid tumors and a Phase ll colorectal cancer trial and has conducted pre-clinical studies with its compounds in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin. Company: Xanthus Pharmaceuticals, Inc. Media Contact: Lisa Terry Investor Relations Contact: Lisa Terry Phone: 617-252-6105 E-mail: [email protected] Web: http://www.xanthus.com Xanthus is a biopharmaceutical company focused on the discovery, development, acquisition and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. We believe that our scientific depth and broad clinical development expertise provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address cancer and autoimmune disorders not adequately treated with existing therapies. Company: ZIOPHARM Oncology, Inc. Ticker Symbol & Exchange: NASDAQ:ZIOP Media Contact: Tina Posterli, 917-322-2565 Investor Relations Contact: Suzanne McKenna Phone: 646-214-0703 E-mail: [email protected] Web: http://www.ziopharm.com ZIOPHARM Oncology, Inc. is a biopharmaceutical company seeking to acquire, develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs that address unmet medical needs. Currently, the Company's two lead products, ZIO-101 and ZIO-201 are in phase I/II studies in advanced myeloma and advanced sarcoma, respectively. Both products are also in ongoing phase I studies in advanced cancers. Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services. Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email [email protected]. |
